• Accepting Children: No
• Accepting New Patients: Yes

• Accepting Medicare: Yes
• Accepting Medicaid/DSHS: Yes

Payment Methods Accepted:

Medicare, Medicaid/DSHS, Bill Insurance, VISA, Master Card, Cash, Check, American Express, Discover Card, Money Order

Insurance Accepted:

Contact this office for accepted insurance plans.

Additional Information:

Internship: Michael Reese Hospital, IL

________________________________________

FACULTY POSITIONS:

1995 – 2003   Medical Director, Swedish Breast Care Center, Swedish Medical Center, Seattle, WA
1994 – Present   Clinical Instructor in Medicine, University of Washington, Seattle, WA
1992 – Present   Medical Oncologist, Swedish Cancer Institute, Seattle, WA

________________________________________

PROFESSIONAL AFFILIATIONS:

American College of Physicians
Puget Sound Oncology Consortium (PSOC)
American Society of Clinical Oncology (ASCO)
Southwest Oncology Group (SWOG)
King County Medical Society
National Surgical Adjuvant Breast and Bowel Project (NSABP)

Philosophy of Care

I see my role as an educator, discussing each patient's medical problems in detail. I work with the patient to formulate a treatment plan. I would describe my practice style as very "interactive."

Medical School

Johns Hopkins, MD

Residency

Michael Reese Hospital, IL

Fellowship(s)

University of Chicago Medical Center, IL

Board Certifications

Oncology; Internal Medicine

Additional Information:

Internship: Michael Reese Hospital, IL

________________________________________

FACULTY POSITIONS:

1995 – 2003   Medical Director, Swedish Breast Care Center, Swedish Medical Center, Seattle, WA
1994 – Present   Clinical Instructor in Medicine, University of Washington, Seattle, WA
1992 – Present   Medical Oncologist, Swedish Cancer Institute, Seattle, WA

________________________________________

PROFESSIONAL AFFILIATIONS:

American College of Physicians
Puget Sound Oncology Consortium (PSOC)
American Society of Clinical Oncology (ASCO)
Southwest Oncology Group (SWOG)
King County Medical Society
National Surgical Adjuvant Breast and Bowel Project (NSABP)

CLINICAL TRIALS:

Dr. Erin Ellis is the lead investigator for the following clinical trials currently available at the Swedish Cancer Institute:

I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2)

A Randomized, Phase III, Open-label Study of Lapatinib plus Trastuzumab versus Trastuzumab as Continued HER2 Suppression Therapy after Completion of First- or Second-line Trastuzumab plus Chemotherapy in Subjects with HER2- positive Metastatic Breast Cancer

________________________________________

PUBLICATIONS:

WI Bensinger, KS Schiffman, L Holmberg, FR Appelbaum, R Maziarz, P Montgomery, E Elllis, S Rivkin, P Weiden, et al. High-dose busulfan, melphalan, thiotepa, and peripheral blood stem cell infusion for the treatment of metastatic breast cancer. Bone Marrow Transplanation, 1997.

Golom HM and Ellis E. Treatment options for hairy cell leukemia. Seminars in Oncology, 18: 7-11, 1991.

Ellis ED, Williams, SF and Golomb HM. Current advances and guidelines in therapy. In benign and malignant lymphadenopathies: A Guide to Clinical and Laboratory Diagosis, edited by GA Pangalis and A Polliak.

Moormeier JA, Williams SF, Kaminer LS, Ellis ED, Garner M, Farah, Weichselbaum RR, and Bitran JD. Autologous bone marrow transplantation followed by involved field radiotherapy in aptients with relapsed or refractory Hodgkin’s disease. Leukemia and Lymphoma.

Ellis ED, Williams, SF, moormeier JA, Mainer LS, and Bitran JD. A phase I-II study of high dose cyclophosphamide, thiotepa and escalating doses of mitoxantrone with autologous stem cell rescue in patients with refractory malignancies. Bone Marrow Transplatnation, 6: 439-442, 1990.

Ellis ED, Moormeier JA and Golomb HM. The treatment of hairy cell leukemia; a review. Leukemia and Lymphoma, 1: 77-85, 1990.

Le Beau MM, Bitter MA, Larson RA, Doane LA, Ellis ED, Franklin WA, Rubin CM, Kadin ME and Varidman JW. The t(2;5)(p23;q35): A recurring chromosomal abnormality in Ki-1 positive anaplastic large cell lymphoma. Leukemia, 3: 866-870, 1989.
________________________________________

ABSTRACTS:

Ellis E, Vokes E, Hoffman P, Krishnasamy S, Gradishar W, English C, Ferguson M, Haraf D, Bitran J and Golomb H. A phase II study of neoadjuvant chemotherapy and concomitant chemoradiotherapy for stage III lung cancer. Proceedings of ASCO, 1991.

Bitran JD, Vokes EE, Hoffman PC, Ellis ED, Gradishar W and Golomb HM. Combines modality therapy for stage III non-small cell lung cancer (NSCLC). Third International Congress on Neoadjuvant Chemotherapy, February 6-9, 1991.

Ellis ED, Williams SF, Moormeier JA, Bitran JD and Ratain MJ. A phase I study of high dose amonafide with autologous bone marrow rescue (ABMR). American Federation for Clinical Research, Midwest Section, November 1, 1990.

Ellis E, Moormeier J, Williams S, Kaminer L, Mick R, Bitran J. A phase II study of mitoxantrone, vincristine, and 5-fluorouracil with leucovorin (MVFL) as induction chemotherapy in women with stage IV breast cancer. 13th Annual San Antonio Breast Cancer Symposium, November 2-3, 1990.

Ellis E, Moormeier J, Kaminer L, Mick R, Williams S and Bitran J. A phase I-II study of high dose cyclophosphamide, thiotepa and mitoxantrone (CTM) in autologous bone marrow reinfusion (ABMR) in patients with refractory malignancies. Proceedings of ASCO, 9: 17, 1990.